Introduction
Hepatic fibrosis is a common pathological feature of progressive chronic liver diseases, and is characterized by abnormal increase in extracellular matrices. It can lead to cirrhosis, and ultimately, end-stage liver failure and increased risk for hepatocellular carcinoma (FRIED-MAN 1999; JONSSON et al. 2001; OHISHI et al. 2001) . The most important cells directly related to hepatic fibrosis are hepatic stellate cells (HSCs, Ito cells) distributed in Disse's cavity. When hepatic parenchymal cells are disturbed, HSCs enlarge, proliferate, and transform into myofibroblasts. These transformed HSCs synthesize and locally excrete a variety of extracellular matrices and promote hepatic fibrosis (FRIEDMAN 1999; OHISHI et al. 2001; IREDALE et al. 1998) .
Transforming growth factor β1 plays a dominant role in the development of fibrosis (JONSSON et al. 2001; SCHUPPAN et al. 2001) . TGF-β1 production may be enhanced by AT-II, the principal effective molecule of the renin-angiotensin system (RAS) (JONSSON et al. 2001; YOSHIJI et al. 2001 ). Tissue RAS is reported to be activated in patients with chronic liver disease, such as cirrhosis (YOSHIJI et al. 2001; HELMY et al. 2000) . AT-II, which is octapeptid produced mainly by proteolytic cleavage of its precursor AT-I by ACE, has many physiological effects, including vascular hormonal secretion, tissue growth and neuronal activities (YOSHIJI et al. 2001) . Recently, a variety of physiological roles of AT-II have been clarified not only in the pathogenesis and maintenance of high blood pressure but also in the stimulation of fibroblast proliferation and collagen synthesis by non-parencimal cells (OHISHI et al. 2001) . AT-II is also considered a potential mediator of intrahepatic portal hypertension, because its plasma levels were increased in patients with cirrhosis, and its administration induced elevation of portal pressure (YOSHIJI et al. 2001) . Several types of AT-II receptors have been identified. The AT-II type 1 receptor (AT1-R) mediates most of the biological effects of AT-II, including increase in the intracellular Ca 2+ concentration, cell contraction, and proliferation (YOSHIJI et al. 2001; ARDAILLOU 1999) .
Captopril, an ACE inhibitor, has been well studied and reported to suppress rat hepatic fibrosis induced by pig serum recently (OHISHI et al. 2001) . Similarly AT1-R antagonists have been shown to reduce the portal pressure in hepatic cirrhosis (SCHNEIDER et al. 1999) .
The aim of present study was to compare the hepatoprotective effects of candesartan cilexetil, an AT1-R blocker, and captopril, an ACE inhibitor, on hepatic fibrosis caused by CCl 4 in rat model.
Material and methods
Animals and experimental design: Male Sprague Dawley rats weighing 240-310 g (11-12 weeks old, n = 38) were used in our experiments. They were obtained from the Yüzüncü Yil Research Hospital Animal Resources Center (Van, Turkey) and maintained under temperature-controlled conditions (22 °C ± 3 °C) with an artificial 12-hour light/dark cycle. The animals were given commercial diet in pellet form and water ad libitum throughout the acclimatization and experimental periods. All animal experiments were approved by the Animal Experimentation Committee of the Faculty of Medicine, Yüzüncü Yil University.
Experimental groups: Thirty-eight rats were divided into 4 experimental groups: The first group was given CCl 4 only (n = 10, CCl 4 alone group); the second was given both CCl 4 and captopril simultaneously (n = 10, CCl 4 /captopril group); the third was given both CCl 4 and candesartan cilexetil simultaneously (n = 10, CCl 4 /candesartan group); fourth was given isotonic sodium chloride (0.9% NaCl) only (n = 8, control group).
Administration of CCl 4 , captopril, candesartan and 0.9%NaCl: NaCl was administrated at the dose of 1.5 ml/kg of body weight three times a week intraperitoneally (ip). CCl 4 (KgaA 64271, Merck, Darmstadt, Germany) was dissolved in olive oil at (1:7) and administered at a dose of 1.5 ml/kg of body weight three times a week ip as described previously (ROJKIND 1973) . The same amount of CCl 4 was used in all experiments. Captopril (100 mg · kg -1 ·day -1 ; Kapril, Mustafa Nevzat, Turkey) was dissolved in the drinking water and was given ad libitum by free drinking throughout the experiments. The captopril dose chosen for this study was based on previous studies that determined the dose, which was effectively attenuating the progression of hepatic fibrosis in rats (JONSSON et al. 2001) . The animals were weighed three times a week, and the volume of captopril consumed over the previous 2 days was recorded. A fresh captopril solution was prepared, the concentration of which was dependent on the average body weight and drinking volume for each cage in every 2 days. Candesartan cilexetil (8 mg·kg  -1 ·day   -1 ; Atacand, Astra, Sweden) was given by gavage (YOSHIJI et al. 2001; ISHIGAI et al. 1997) . The volume of supplied drinking water was measured and was found to be almost equal between the groups. On average, a rat drank water for about 20-25 ml/day.
At the end of 7 th week, all animals were sacrificed under ether anesthesia, and terminally bled via cardiac puncture. The blood was centrifuged and serum was stored at -20 °C for use. The liver, kidney and heart of each animal were removed. Tissue samples were fixed in 10% buffered formalin and embedded in paraffin for histological examination.
Histological and immunohistochemical analysis: Formalin fixed, paraffin-embedded sections of liver were cut at 4 µm and stained with hematoxylin-eosin (H&E), and reticulin. The sections were coded and histology was evaluated by a single pathologist (S.U.) without knowledge of treatment groups or laboratory data. Fibrosis was staged as 0-4, based on Scheuer's (SCHEUER 1991) scoring system as follows: stage 0, no fibrosis; stage 1, expansion of the portal tracts without linkage; stage 2, portal expansion with portal to portal linkage; stage 3, extensive portal to portal and focal portal to central linkage; and stage 4, cirrhosis.
Immunohistochemical staining of smooth muscle actin (α-SMA) was performed on sections of formalin-fixed, parafin-embedded liver to detect activated myofibroblasts using a α-SMA antibody (clone 1A4; Dako, Copenhagen, Denmark) by previously described methods (YOSHIJI et al. 2001; SAKAIDA et al. 1998 ). The liver sections of the all groups were stained with α-SMA antibody including 0.9% NaCl -only group which was served as the control. We did not count α-SMA positive vessels in the portal area, which were assumed to be hepatic arteries. We only counted α-SMA-positive cells in the sinusoidal lining. Positive cells were counted at 40× magnification using an ocular micrometer. For each specimen, 10 randomly selected areas were counted and mean numbers of the cells were calculated.
At the end of the experiment, total protein, albumin, direct/indirect bilirubin, gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and protrombin time (PT) were analyzed using a Hitachi Modular P-880 Analyzer (Roche, Germany).
Statistical analysis: Data were represented as the mean ± SD. Both parametric and nonparametric techniques were used for analysis. Analysis of variance (ANOVA) with Tukey's post-hoc comparison was used to test for differences in medians between treatment groups. Chi-square test was used to test histopathological changes between each group. A p value < 0.05 was considered statistically significant.
Results
Three animals (two CCl 4 /captopril group, one CCl 4 /candesartan group) died during experimental peri-fects. The mean fibrosis score was significantly lower in the CCl 4 /candesartan group compared with CCl 4 -alone group and CCl 4 /captopril group (p < 0.001). Inflammation was generally mild in CCl 4 /candesartan group compared with CCl 4 -alone group and CCl 4 /captopril group (p < 0.01) and although there was a trend for inflammation to be lower in the candesartan-treated rats (table 2) .
Immunohistochemistry
Immunohistochemical analysis of α-SMA was performed to examine the effect of these RAS inhibitory agents on HSC activation. In control group α-SMA stainig was mainly confined to the portal area and only very few α-SMA-positive cells were present in the parenchyme. The activated HSCs in liver sections from CCl 4 -alone group and CCl 4 /captopril group, which express α-SMA and are therefore named myofibroblastlike cells, were significantly increased ( fig. 3C, D ) compared with CCl 4 /candesartan group and 0.9% NaCl group ( fig. 3A , B) (p < 0.001). Candesartan treatment significantly reduced the number of α-SMA-positive cells (fig. 4) . These results suggested that prevention of fibrogenesis by candesartan appeared to be related to the suppression of HSC activation and proliferation.
od. In the CCl 4 alone and CCl 4 /captopril group body weights decreased more compared to CCl 4 /candesartan and control group but these changes were not statistically significant (p > 0.05). Candesartan and captopril have a beneficial effect on serum levels of creatinine, AST, and ALT. Candesartan treatment also had a beneficial effect on serum levels of ALP (see table 1).
Histological findings
Histopathological evaluation and comparisons of liver specimens was made between the experimental groups. Histopathological changes were indicated in the figures (fig. 1A, B, C, D) . Histological examination of liver obtained 7 weeks after the start of treatment showed that CCl 4 -alone group and CCl 4 /captopril group had developed severe (stage 3 or 4) fibrosis, characterized by ballooning degeneration, acidophilic bodies, extensive portal-portal and portal-central fibrous linkage, distortion of liver architecture, marked regeneration nodule.
In contrast, severe hepatic fibrosis was not detected in rats treated by CCl 4 /candesartan ( fig. 2A, C) and 0.9% NaCl ( fig. 2B ). Candesartan markedly inhibited progression of hepatic fibrosis and mononuclear cell infiltration, whereas captopril did not show significant preventive ef- 
Discussion
Liver fibrosis is characterized by increased deposition and altered composition of extracellular matrix, in such way as there is an excess of collagens I, III, IV. Hepatic stellate cells (HSC) are central to the process of fibrosis as the major source of fibrillar and nonfibrillar matrix proteins. The inhibition of hepatic fibrosis is beneficial in preventing progression of chronic liver disease (JONS- SON et al. 2001; OHISHI et al. 2001; KNITELL et al. 1999; BATALLER et al. 2000) .
Drugs modulating the action of vasoactive substances are currently used in the treatment of different types of human fibrosis (KLAHR and MORRISSEY 2000) . These vasoactive substances include vasoconstrictors (AT-II, aldosterone, and endothelin-1) and vasodilators (prostaglandins and nitric oxide). Among these factors, AT-II appears to play an important role (OHISHI et al. 2001; YOSHIJI et al. 2001; MATSUSAKA et al. 1999; NODA et al. 1999) . Recently, several studies have demonstrated that ACE inhibitors attenuate progression of hepatic fibrosis. One of the ACE inhibitors, captopril has been well studied and reported to suppress rat hepatic fibrosis (JONSSON et al. 2001; OHISHI et al. 2001; RAMOS et al. 1994) .
In our study, we showed that candesartan cilexetil, AT1-R blocker, significantly reduced hepatic fibrosis induced by CCl 4 . Our findings demonstrated that there were considerable differences between the hepatoprotective effects of candesartan and captopril in vivo. Although, candesartan administration significantly ameliorated the progression of hepatic fibrosis, captopril did not show similar effects. These results suggest that candesartan directly inhibits hepatic fibrogenesis induced by CCl 4 . In addition to antifibrotic effects, candesartan treatment had a beneficial effect on serum liver enzymes. Our results showed coherence with those reported by Yoshiji (YOSHIJI et al. 2001) .
The difference between candesartan cilexetil and captopril with regard to hepatoprotective effects may be explained as follows; first, the inhibition of ACE by an ACE inhibitor results in the accumulation of bradikinin. Bradikinin plays an important role in the progression of fibrosis, stimulating the proliferation of mesangial cells. Bradikinin also activated TGF-β1, which plays a pivotal role in the accumulation of extracellular matrix proteins (NODA et al. 1999; EL-DAHR et al. 1996) . Second, AT1-R antagonists can completely inhibit AT-II's effects at the level of AT1-R, whereas captopril cannot inhibit the effect of AT-II. Third, AT1-R antagonists are reported to activate AT2-receptors via the elevation of plasma AT-II (NODA et al. 1999 ).
In the current study, we have shown that the number of α-SMA-positive cells in the livers from CCl 4 /candesartan-treated rats dramatically reduced compared with CCl 4 -alone group and CCl 4 /captopril group, suggesting that AT1-R blocker suppresses activation and proliferation of hepatic stellate cells in response to CCl 4 ( fig. 3B) .
In this study, the hepatoprotective effects of candesartan cilexetil and captopril were investigated in hepatic fibrosis. We have shown that candesartan cilexetil effectively delayed the progression of hepatic fibrosis, whereas captopril did not show similary beneficial effect on hepatic fibrosis. In conclusion, significant differences were documented between the beneficial effects of candesartan cilexetil and captopril on hepatic fibrosis. Our results suggest that AT1-R antagonist candesartan cilexetil may be useful agent for trials in human chronic liver diseases associated with fibrosis. More prolonged follow-up studies should be performed to clarify this results. 
